According to the article, the cost is more and you may not feel the customary “puff” as much with the new devices. The new devices tend to clog easier. The reason for the change, the ozone and chlorofluorocarbon that damage, so even the asthma inhalers are going green, not literally I think...
This is the second approval this week for a generic version of Wellbutrin, earlier this week Watson Pharmaceuticals announced it’s new version. BD The Food and Drug Administration approved a generic copy of an antidepressant made by Impax Laboratories Inc. Regulators gave the drug — a copy of GlaxoSmithKline...
The entire focus is to see whether or not patent laws have been violated and if less expensive generics were in any way stalled from getting to the market place. It all boils down to intellectual-property rights and patient disputes. Interesting that Teva is settling lawsuits and will be...
Posted to
The Medical Quack .... by Barbara Duck
on 11-26-2008
Filed under: Medically Related, Pharma/FDA News, Pharma, Generic Drugs, Intellectual property, Lawsuits, Teva, Europe, anti trust
Some issues are a result of still being paper driven as timely reports and real time information are not available, but they are not the only government agency in this scenario, only one of the most critical though. Also, some members of Congress don’t use computers either and felt uncomfortable...
Posted to
The Medical Quack .... by Barbara Duck
on 11-26-2008
Filed under: Medically Related, Technology, Pharma/FDA News, personalized medicine, healthcare, Medical Records, Pharma, FDA, Congress, integration, CMS, Leavitt
Nothing new here in what has been posted, but this time the predictions are coming from within Ernst and Young from India. BD The Indian clinical trials market is predicted to continue its growth despite the current financial climate, according to a partner at Ernst & Young India’s Healthsciences...
Posted to
The Medical Quack .... by Barbara Duck
on 11-25-2008
Filed under: Medically Related, Pharma/FDA News, healthcare, Pharma, clinical trials, R and D, India, Economics, Outsourcing, Employment, Clinic
Here’s the ribbon breaking ceremony picture. Let’s all hope this is a success and hopefully some new technology will enter the picture as well with remote batch monitoring of products manufactured in China and other locations in the world. There is only so much an in person visit can cover...
Posted to
The Medical Quack .... by Barbara Duck
on 11-19-2008
Filed under: Medically Related, Technology, Pharma/FDA News, Pharma, FDA, China, Outsourcing, Tainted Food, food contamination, food safety, busines intelligence software, server banks, import/exports, FDA inspections
This indeed makes it much more difficult to pin down and see which physicians are using which drugs, but from their own internal sales information each drug company will have sales from drug stores, so the overall business from a pre set territory can be derived, so perhaps a new curve in Pharma marketing...